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DOI 10.1016/j.ccr.2010.08.008SUMMARYBMK1 is activated by mitogens and oncogenic signals and, thus, is strongly implicated in tumorigenesis. We
found that BMK1 interacted with promyelocytic leukemia protein (PML), and inhibited its tumor-suppressor
function through phosphorylation. Furthermore, activated BMK1 notably inhibited PML-dependent activa-
tion of p21. To further investigate the BMK-mediated inhibition of the tumor suppressor activity of PML in
tumor cells, we developed a small-molecule inhibitor of the kinase activity of BMK1, XMD8-92. Inhibition
of BMK1 by XMD8-92 blocked tumor cell proliferation in vitro and significantly inhibited tumor growth
in vivo by 95%, demonstrating the efficacy and tolerability of BMK1-targeted cancer treatment in animals.INTRODUCTION
Four MAP kinase pathways exist in mammalian cells: ERK1/2,
JNK, p38, and BMK1 (Chang and Karin, 2001; Johnson and
Lapadat, 2002; Pearson et al., 2001; Raman et al., 2007). BMK1
is most similar to ERK1/2 because both contain the Thr-Glu-Tyr
dual phosphorylation motif. However, unlike ERK1/2, BMK1
has a unique activating loop structure and an uncommonly large
C-terminal nonkinase domain. The C-terminal half of BMK1
contains a nuclear localization signal (NLS) that is critical for
nuclear localization of BMK1 (Lee et al., 1995). The ERK1/2 and
BMK1 cascades are both activated by mitogens and by onco-
genic signals and, thus, are strongly implicated in tumorigenesis
(Chang and Karin, 2001; Johnson and Lapadat, 2002; Kato et al.,
1997, 1998; Pearson et al., 2001). Specifically, deregulated
BMK1 signaling has been associated with properties of humanSignificance
TheBMK1/ERK5 pathway is the last discovered and the least st
the development of the small-molecule inhibitor for BMK1 tha
inhibitor, we determined that BMK1 inhibits the tumor suppress
strated the efficacy and tolerability of BMK1-targeted cancer tr
tumor cells, our results suggest that cancer therapies targeting
of human tumors.
258 Cancer Cell 18, 258–267, September 14, 2010 ª2010 Elsevier Inmalignancies including chemoresistance of breast tumor cells
(Weldon et al., 2002), uncontrolled proliferation of ErbB2-overex-
pressing carcinomas (Esparis-Ogando et al., 2002), metastatic
potential of prostate tumor cells (Mehta et al., 2003), and
tumor-associated angiogenesis (Hayashi et al., 2005).
Three sequentially activated kinases make up the central core
of the MAP kinase module: a MAP kinase kinase kinase, or
MEKK; a MAP kinase kinase, or MEK; and a MAP kinase. The
signaling core in the BMK1 pathway consists of the kinases,
MEKK2/MEKK3, MEK5, and BMK1 (Hayashi and Lee, 2004).
MEK5 is the only known direct upstream regulatory kinase of
BMK1 (Kato et al., 1997). However, MEK5 can be inhibited by
inhibitors of MEK1/2 (Kamakura et al., 1999; Mody et al.,
2001), such as PD98059 and U0126, which have been consid-
ered as specific inhibitors of the ERK1/2 pathway. As such,
experimental results produced using these two inhibitors needudiedmammalianMAP kinase cascade. Herein, we describe
t is effective not only in cells but also in animals. Using this
or activity of cellular PML, andmore importantly, we demon-
eatment in animals. As BMK1 is expressed in most, if not all,
BMK1 will have broad application for treating diverse types
c.
Figure 1. Development of a Pharmacolog-
ical Inhibitor of BMK1
(A) Chemical structure of XMD8-92.
(B) HeLa cells were serum starved overnight
followed by treatment with 1 or 5 mM XMD8-92 or
1 mM PD184352 as indicated for 1 hr. Cells were
then stimulated with EGF for 17 min and BMK1
activation was detected by mobility retardation
(Abe et al., 1996). ERK1/2 activation was detected
by an antiphospho-ERK1/2 (T202/Y204) antibody.
(C) HEK293 cells were cotransfected with expres-
sion plasmids of MEK5D and BMK1. After 48 hr,
BMK1 was immunoprecipitated and in vitro kinase
assays were carried out in the presence of the
indicated amount of XMD8-92. The ATP concen-
tration was measured by the Kinase-Glo Lumines-
cent Kinase Assay Platform. Kinase activity is
expressed relative to the kinase activity in cells
without XMD8-92 treatment, which was taken
as 1. n = 3, ± standard error of mean (SEM).
(D) Expression plasmids of MEK5D and BMK1
were transfected into HEK293 as indicated.
After 36 hr, these cells were cotransfected with
vectors for pCMV-b and the reporter plasmid
pG5ElbLuc along with a GAL4 fusion expression
vector containing MEF2C for 3 hr and then treated
with 5 mM XMD8-92 for a further 16 hr. The lucif-
erase activities were normalized against cells
transfected with pG5ElbLuc and pGAL4 reporter
plasmid alone, whose value was taken as 1.
n = 3, ± SEM, *p < 0.01.
(E) HeLa cells were infected with Ad-EV or Ad-
BMK1(AEF), as indicated, 24 hr before treatment
with or without XMD8-92 (5 mM) for 48 hr, followed
by MTT assays. % growth inhibition = (1  MTT
value of cells in each experimental group/MTT
value of cells treated with Ad-EV only) 3 100.
n = 3, ± SEM.
(F) Immunofluorescent analysis of CD31 (red) and
TUNEL (green) in heart sections from control and
XMD8-92 treated. DNase treatments were used
as positive controls for TUNEL staining. Scale bar
represents 100 mm. n = 6 mice, n = 10 slices.
See also Figure S1 and Tables S1–S5.
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and the ERK1/2 cascades. So far, there is no specific small-
molecule inhibitor of BMK1 that is effective both in cells and
animals. More importantly, the lack of this kind of BMK1 inhibitor
has hampered the understanding of the physiological/patholog-
ical roles of BMK1 through cellular and animal studies.
RESULTS
Development of Pharmacological Inhibitors of BMK1
During the course of developing isoform-selective polo kinase
inhibitors, we synthesized a library of analogs of the highly selec-
tive, adenosine triphosphate (ATP)-competitive polo kinase
inhibitor, BI-2536 (Steegmaier et al., 2007). By screening a subset
of the library against a diverse panel of 402 kinases, wewere able
to explore the full range of potential kinase targets of this class
of compounds (Goldstein et al., 2008). We discovered that
expansion of the 6-membered aliphatic ring of BI-2536 to a
7-membered ring containing an anthranilic acid resulted in lossCanof polo kinase inhibition activity but serendipitously resulted in
compounds that exhibited high selectivity toward BMK1. Struc-
ture-activity guided optimization based on the ability of the
compounds to inhibit cellular BMK1 autophosphorylation stimu-
lated by EGF (Kato et al., 1998) in conjunction with kinase selec-
tivity analysis resulted in the synthesis of XMD8-92 (Figure 1A).
The kinase selectivity of XMD8-92 was determined by profiling
the inhibitor at a concentration of 10 mM against a panel of 402
diverse kinases using an in vitro ATP-site competition binding
assay (Fabian et al., 2005; Karaman et al., 2008). Kinases that
exhibited >90% displacement by XMD8-92 were determined
to be BMK1, DCAMKL1, DCAMKL2, TNK1, and PLK4. XMD8-
92 exhibited the greatest affinity toward BMK1 with a measured
dissociation constant (KD) of 80 nM, while DCAMKL2, TNK1, and
PLK4 exhibited KDs of 190, 890, and 600 nM, respectively (see
Table S1 available online). This represents a remarkable level
of selectivity considering the very large number of kinases
that have been assayed. Moreover, XMD8-92 was profiled
against all detectable kinases in HeLa cell lysates using thecer Cell 18, 258–267, September 14, 2010 ª2010 Elsevier Inc. 259
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BMK1 Inhibits PML ActivityKiNativ method (Patricelli et al., 2007) and was found to be about
10-fold more selective for BMK1 with a IC50 of 1.5 mM than the
most potent off-targets, TNK1 (IC50 = 10 mM) and ACK1 (also
known as TNK2, IC50 = 18 mM). Other weak off-targets included
the kinase domain 2 of RSK1 and RSK2, PIK4A and PIK4B, and
FAK (Table S2). Notably, MEK5 was not significantly inhibited by
XMD8-92 at up to 50 mM. There is also no significant inhibitory
effect of XMD8-92 on TNK1 and PLK4 detected in vitro and
in vivo (Figure S1). The BMK1 potency and selectivity determined
by the KiNativmethod support the conclusion that the anticancer
effects of XMD8-92 detailed herein are due to inhibition of BMK1.
We tested the effect of XMD8-92 on the cellular activity of
BMK1. Growth factor-induced activation of cellular BMK1, but
not the structurally similar ERK1/2, was effectively blocked by
1 mM XMD8-92 (Figure 1B), while PD184352, an ERK1/2 inhib-
itor, only blocked ERK1/2 but not BMK1 activation by EGF
(Figure 1B). XMD8-92 also significantly reduced BMK1 activity
in in vitro kinase assays (Figure 1C). In addition, trans-reporter
assays showed that XMD8-92 dramatically reduced the BMK1-
dependent transactivating activity of MEF2C, a known substrate
for BMK1 (Kato et al., 1997) (Figure 1D).
As the BMK1 pathway is critical for cell proliferation (Kato
et al., 1998), we next tested whether XMD8-92, through its
specific ability to block BMK1 activity, has an antiproliferative
effect on cells. The extent of inhibition by XMD8-92 in HeLa cells
is indistinguishable from that by dominant negative BMK1,
BMK1(Ala-Glu-Phe [AEF]), administered through infection with
recombinant adenovirus encoding BMK1(AEF), Ad-BMK1(AEF)
(Figure 1E). The inhibitory effect of XMD8-92 on proliferation
was observed in a wide variety of cancer cell lines (Figure S2).
Moreover, additional treatment of Ad-BMK1(AEF)-infected
HeLa cells with XMD8-92 did not have a further inhibitory effect
when compared to cancer cells treated with XMD8-92 alone
(Figure 1E), indicating that at least some of the antiproliferative
capacity of XMD8-92 is through inhibition of the activity of BMK1.
Subsequently, to assess the utility of XMD8-92 in animal
experiments, we analyzed the pharmacokinetics and tolerability
of XMD8-92. The pharmacokinetics of XMD8-92 was evaluated
in Sprague-Dawley rats given a single intravenous or oral dose.
XMD8-92 was found to have a 2.0 hr half-life clearance of
26 mL/min/kg. The compound had moderate tissue distribution
with a calculated volume of distribution of 3.4 L/kg. XMD8-92
had high oral bioavailability with 69%of the dose absorbed. After
a single oral dose of 2 mg/kg, maximal plasma concentrations of
approximately 500 nM were observed by 30 min, with 34 nM
remaining 8 hr postdose (Figure S1). In tolerability experiments
(Tables S3, S4, and S5), high plasma concentrations of drug
(10 mMafter intraperitoneal [IP] dosing of 50mg/kg) weremain-
tained throughout the 14 days. The drug appeared to be well
tolerated and the mice appeared healthy with no sign of distress.
No vasculature instability was observed in the XMD8-92-treated
mice (Figure 1F; Tables S4 and S5). Together, these results
demonstrated that XMD8-92 is an effective and specific inhibitor
of BMK1 in vitro and in vivo.
BMK1 Is in Complex with PML and Suppresses
Its Anticancer Activity
To study themolecularmechanismbywhichBMK1 regulates cell
proliferation, we carried out mass spectrometry (MS) analysis of260 Cancer Cell 18, 258–267, September 14, 2010 ª2010 Elsevier Incellular BMK1-interacting proteins and revealed that BMK1 inter-
acted with promyelocytic leukemia protein (PML) (Table S6).
Western blot analysis using two different anti-PML antibodies
showed that PML coprecipitated with BMK1 (Figure 2A) and
that reciprocal immunoprecipitation of PML using anti-PML
antibody brought down cellular BMK1 (Figure 2B). These data
indicate that endogenous BMK1 is in complex with PML.
As PML is a tumor suppressor and known to regulate cell
proliferation, we next tested whether BMK1 controls the anti-
tumor function of PML. We found that p21, one of the down-
stream effectors of PML and a key modulator of cell proliferation
(Bernardi and Pandolfi, 2007; Salomoni and Pandolfi, 2002), was
significantly induced when the expression level of BMK1 was
suppressed by siRNA (Figure 2C). Inhibition of BMK1 activation
by XMD8-92 also significantly induced p21 expression in cells
(Figure 2D), and its induction was substantially reduced in PML
null cells (Figure 2D). Using PML-knockdown cell lines, we also
demonstrated that PML and p21 are involved in XMD8-92-medi-
ated suppression of cancer cell proliferation (Figure S2). These
results indicated that BMK1 not only is in complex with PML
but also suppresses the expression of the cell-cycle regulator
p21, through inhibiting the antitumor function of PML.
BMK1 Suppress PML Function through Phosphorylation
Since BMK1 is known to regulate the activity of cellular proteins
through phosphorylation (Hayashi et al., 2001; Kato et al., 1997;
Kato et al., 2000), we carried out an in vitro kinase assay using
activated BMK1 kinase and recombinant PML as substrate, fol-
lowed by mass spectrometry analysis (details in Experimental
Procedures) to map the potential phosphorylation sites on
PML by BMK1. We identified that S403 and T409 of PML as
potential phosphorylation sites (Figure 3A). Mutation of these
two sites to alanine significantly inhibited the phosphorylation
of PML by BMK1 in an in vitro kinase assay (Figure 3B) indicating
these two sites in PML are major phosphorylation sites by the
BMK1 kinase. PML phosphorylation by BMK1 in vivo was also
demonstrated (Figure S3). We next mutated S403 and T409 to
aspartic acid (PML-2D) to mimic the phosphorylation of PML
by BMK1. We found that recombinant adenovirus-mediated
expression of PML2D (S403D/T409D) in PML-deficient cells
did not significantly restore their responsiveness to XMD8-
92-dependent p21 induction unlike wild-type PML, which did
restore responsiveness (Figure 3C). As PML is known to modu-
late p21 through p53 (Guo et al., 2000), the role of BMK1 on
p53 regulation is still not clear (Figure S4). These results indicate
that BMK1 suppresses PML function through phosphorylation of
S403 and T409 of PML (Figure 3C).
Activated BMK1 Translocates from the Cytosol
to Colocalize with PML in the Nucleus
It has been shown that, on activation, BMK1 translocates from
the cytoplasm to the nucleus (Kondoh et al., 2006; Yan et al.,
2001). As PML is known to localize to the PML-nuclear body
(PML-NB), through which it mediates diverse cellular functions,
we wondered whether BMK1, after activation, could move to
the nucleus and colocalize with PML in PML-NBs.We expressed
a dominant negative form of MEK5, MEK5A (Kato et al., 1997), to
inhibit the activation of BMK1 in cells (Figure 4, first-row panels).
Conversely, we expressed a dominant active form of MEK5,c.
Figure 2. BMK1 is in Complex with PML and Suppresses the Anti-
cancer Function of PML in Tumor Cells
(A) Cellular BMK1 was immunoprecipitated from cell lysates from A549 and
HeLa cells with anti-BMK1 antibody or rabbit IgG, as control. The resultant
immunoprecipitates and total cell lysates were then tested for the presence
of PML using anti-PML antibody.
(B) Endogenous PML was immunoprecipitated from cell lysates of A549 and
HeLa cells with anti-PML antibody or rabbit IgG, as control. The existence of
BMK1 in these immunoprecipitates was analyzed using western blots as
described in (A).
(C) HeLa and A549 cells were transfected with control or BMK1-specific
siRNA. Cell lysates were analyzed by western blot using anti-p21 or anti-
GAPDH antibodies as noted. n = 3, ± standard error of mean (SEM), *p < 0.01.
(D) Pml+/+ MEF and Pml/ MEF cells were treated with or without XMD8-92
(5 mM) for 16 hr as indicated. Cell lysates were analyzed by western blot using
anti-p21 antibody. The levels of p21 protein expression were quantified by
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CanMEK5D, to keep BMK1 activated in cells (Figure 4A, second-row
panels). With increased expression of PML in cells, activated
BMK1 is colocalized with PML in the PML-NBs (Figure 4A,
fourth-row panels) whereas nonactivated BMK1 stays in the
cytoplasm (Figure 4A, third-row panels). BMK1 contains a kinase
domain in its N-terminal half and a nonkinase domain in its
C-terminal half (Figure 4B). We next tested the involvement of
these two domains in the colocalization of activated BMK1 and
PML in PML-NBs. We demonstrate that the kinase region, but
not the nonkinase region, of BMK1 is sufficient for the colocaliza-
tion of BMK1 and PML in PML-NBs (Figure 4B). This result indi-
cates that BMK1, on activation, translocates from the cytosol to
the nucleus and, through its kinase domain, colocalizes with
PML in PML-NBs (Figure 5).
BMK1 Is a Potential Drug Target for Treating Cancer
To evaluate the effectiveness of XMD8-92 in inhibiting the
activity of BMK1 in tumors, we tested the compound in mice
xenografted with human tumors. XMD8-92 was found to effec-
tively inhibit BMK1 activation as well as induce PML’s down-
stream effector, p21 (Figure 6A). More importantly, treatment
of the mice with XMD8-92 1 day, several days, or weeks after
inoculation of the tumor cells all significantly inhibit the
growth of the xenografted human or syngeneic mouse tumors
(Figure 6B), without obvious side effects to the animals. Immu-
nostaining of tumor sections showed that XMD8-92 effectively
inhibited the incorporation of BrdU during tumor cell division
(Figure 6C) indicating XMD8-92 blocks tumor cell proliferation,
one of the anticancer effects of PML. As both BMK1 and PML
are involved in angiogenesis (Bernardi et al., 2006; Borden and
Culjkovic, 2009; Hayashi et al., 2004, 2005), we tested whether
XMD8-92 blocks angiogenesis in vivo and found that XMD8-92
significantly inhibits basic fibroblast growth factor (bFGF)
induced angiogenesis in Matrigel plugs (Figure 6D). These
results indicated that XMD8-92 exerts its antitumor effect by
blocking tumor cell proliferation and tumor-associated angio-
genesis, and, possibly, through other BMK1-dependent mecha-
nisms yet to be tested or discovered.
We further examined whether the antitumor effect of XMD8-92
is specific to its anti-BMK1 capacity. The extent of tumor growth
inhibition by XMD8-92 is identical to that elicited using dominant
negative BMK1 administered through intratumoral injection of
Ad-BMK1(AEF) (Figure 7A). Importantly, the additional treatment
of Ad-BMK1(AEF) did not have a further inhibitory effect on the
tumor-bearingmice treated with XMD8-92 alone (Figure 7A) indi-
cating the antitumor capacity of XMD8-92 is, at least partly,
through blocking the activity of BMK1.
We next evaluate the role of PML in XMD8-92-dependent inhi-
bition of tumor growth. We found that depleting PML in tumor
cells significantly lowered, but did not completely abrogate,
the inhibitory effect of XMD8-92 on their growth in mice
(Figure 7B). As XMD8-92 inhibits tumor cell proliferation and neo-
vascularization (Figures 6C and 6D), the reason why PML deple-
tion in tumor cells can only partly reverse the antitumor effect ofdensitometry and normalized against GAPDH. The amount of the p21 protein
in the Pml+/+ MEF without XMD8-92 treatment was taken as 1. n = 5, ± SEM,
*p < 0.01.
See also Figure S2 and Table S6.
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Figure 3. BMK1 Regulates PML Function through Phosphorylation
(A) A schematic representation of wild-type and mutant PMLs. The amino acid
sequences of potential BMK1 phosphorylation sites in PML are indicated.
(B) Mutation of potential BMK1 sites in full-length PML reduces phosphoryla-
tion by BMK1. Equal amounts of full-length wild-type or mutant recombinant
PMLs were subjected to in vitro BMK1-mediated phosphorylation assay of
PML in the presence of activated recombinant BMK1. The levels of relative
[g32P]-incorporation in PML or PML mutants were quantified by densitometry
and normalized against the loading amount of PML or PML mutants in each
reaction mix, respectively. The value of relative [g32P]-incorporation of the
wild-type PML by BMK1 was taken as 100%. n = 3, ± standard error of
mean (SEM), *p < 0.01.
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262 Cancer Cell 18, 258–267, September 14, 2010 ª2010 Elsevier InXMD8-92 may be that PML in tumor cells is responsible only
for mediating XMD8-92-mediated growth arrest of cancer cells
and not for XMD8-92-dependent angiogenesis inhibition. More-
over, increasing the expression level of wild-type PML in these
PML-knockdown (KD) tumor cells restored their sensitivity to
XMD8-92-mediated inhibition of tumor growth (Figure 7B). In
contrast, expression of PML2D in the PML-KD cells did not
re-establish their responsiveness to XMD8-92-mediated sup-
pression of tumor proliferation (Figure 7B). These data indicate
that PML plays a role in XMD8-92-mediated suppression of
tumor growth.
Taken together, these results demonstrated that the BMK1
pathway in animals can be blocked effectively by a small-mole-
cule inhibitor without apparent adverse effects and, more impor-
tantly, BMK1 inhibition is a very effective way to prevent cancer
development in animals.
DISCUSSION
The promyelocytic leukemia protein PML (also called MYL,
RNF71, PP8675, or TRIM19) has been implicated in the regula-
tion of a range of cellular functions, such as inhibition of prolifer-
ation, induction of cellular senescence and apoptosis, as well as
maintenance of genomic stability (Bernardi and Pandolfi, 2007).
It is well known that compromising PML anticancer function by
gene translocation (to produce the PML-RAR fusion protein)
leads to acute promyelocytic leukemia. PML-RAR fusion protein
not only represses PML function but also represses transcrip-
tional activity mediated by RAR-RXR, thereby disrupting retinoid
signaling (Altucci and Gronemeyer, 2001). Although the physio-
logical roles of PML are not yet fully understood, the tumor-
suppressive function of PML is generally recognized (Bernardi
et al., 2006; Salomoni and Pandolfi, 2002; Trotman et al.,
2006). One of the critical anticancer/antiproliferative functions
of PML is through activation of the tumor suppressor, p21,
through transcriptional regulation of p53 (Bernardi and Pandolfi,
2007; Bernardi et al., 2004; Fogal et al., 2000; Guo et al., 2000;
Pearson et al., 2000; Pearson and Pelicci, 2001). Previous
reports have described the regulation of PML through phosphor-
ylation by kinases such as ERK1/2 and CK2 (Hayakawa and
Privalsky, 2004; Scaglioni et al., 2006). Herein, we report
that the mitogenic MAP kinase, BMK1, interacts with PML
and suppresses its antitumor actions such as p21 activation.
However, the effect of BMK1 on p53 regulation is not clear
(Figure S4) and needs further investigation. Because BMK1
negatively regulates PML tumor suppressor function and
BMK1 is activated by a variety of deregulated oncogenes (e.g.,
Her2, Ras, and STAT3), it is likely that the oncogene-induced
BMK1 activation increases the proliferation/survival/chemo-
resistance potential of tumor cells by dampening the anticancer
capacity of PML.(C) Pml/MEF cells were infected with Ad-EV, Ad-PML or Ad-PML2D as indi-
cated. Three days later, these cells were treated with or without XMD8-92
(5 mM) for 16 hr as noted. The expression levels of p21 were quantified as
described in Figure 2D except that the amount of the p21 protein in the
Ad-EV-infected Pml/ cells without XMD8-92 treatment was taken as 1.
n = 3, ± SEM, *p < 0.01.
See also Figure S3.
c.
Figure 4. Activated BMK1 Translocates from the Cytosol to Colocal-
ize with PML in the Nucleus
(A) Fluorescent microscopy images of HeLa cells transfected with expression
vectors encoding BMK1, PML, MEK5A, or MEK5D, as indicated. These cells
were stained with anti-BMK1 (green, first-column panels) or with anti-PML
(PG-M3) antibody (red, second-column panels) as noted. Nuclei were shown
by DAPI staining (blue, third-column panels). Merged images (yellow, fourth-
column panels). n = 5. Scale bar represents 10 mm.
(B) Fluorescent microscopy images of HeLa cells transfected with expression
vectors encoding the N-terminal kinase domain of BMK1 (BMK1-KD), the
C-terminal nonkinase domain of BMK1 (BMK1-NKD) and/or PML, as indi-
cated. These cells were stained with anti-BMK1 (green, first-column panels)
or with anti-PML (PG-M3) antibody (red, second-column panels) as noted.
Nuclei were shown by DAPI staining (blue, third-column panels). Merged
images (yellow, fourth-column panels). n = 5. Scale bar represents 10 mm.
See also Figure S4.
Figure 5. Scheme for PML Regulation by BMK1
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CanBMK1 promotes tumor development not only by inhibiting the
PML tumor suppressor described herein but also by supporting
tumor angiogenesis (Hayashi et al., 2005; Hayashi and Lee,
2004; Pi et al., 2005), tumor metastasis (Sawhney et al., 2009;
Sticht et al., 2008; Zhou et al., 2008) and chemo-resistance of
tumor cells (Weldon et al., 2002). In addition, no significant
feed-back compensatory activation of any other signaling
pathway was detected, so far, by blocking the BMK1 pathway
using XMD8-92 (Figure S4). Conditional knockout of BMK1 in
various tissues of mice (e.g., in cardiomyocytes, neurons, hepa-
tocytes, and T and B cells) has no obvious effect on the develop-
ment, behavior, reproduction and aging of the animals (Hayashi
and Lee, 2004), suggesting that BMK1 should be an attractive
target for pharmaceutical intervention in cancer therapy.
However, the instability of the vasculature observed in mice
depleted of endothelial BMK1 (Hayashi et al., 2004) has discour-
aged the therapeutic development of a BMK1 inhibitor.
Compared to BMK1 knockout, which is much more severe as
it leads to complete and irreversible annihilation of BMK1 gene
product in the tissues targeted, pharmaceutical inhibition of
BMK1 only targets the kinase activity of the enzyme. Therefore,
we believe that applying the BMK1 inhibitor in animals should
have no or little unfavorable effect on vascular integrity. Indeed,
we have demonstrated that XMD8-92 is a very effective ATP-
competitive inhibitor that inhibits BMK1 activity in animals and
reduces tumor growth by 95% without inducing vasculature
abnormalities (Figure 1F; Tables S4 and S5). These results
strengthen the notion that blocking the BMK1 pathway may be
an effective approach for treating human cancer.
EXPERIMENTAL PROCEDURES
KiNativ Profiling Method
KiNativ profiling of XMD8-92 was carried out with both an ATP and adenosine
diphosphate (ADP) acylphosphate-desthiobiotin as described previously
(Patricelli et al., 2007) with the following modifications. HeLa cell lysatescer Cell 18, 258–267, September 14, 2010 ª2010 Elsevier Inc. 263
Figure 6. BMK1 Is a Potential Drug Target for Treating Cancer
(A) A549 cells were injected subcutaneously into the flanks of NOD/SCID mice. After 3 weeks, these tumor-bearing mice were injected intraperitoneally with
XMD8-92 or vehicle for 2 days. The XMD8-92 concentration in these tumors were analyzed and shown in the Supplemental Information (see also Figure S5).
The tumor homogenates were used to detect both BMK1 activity and p21 expression using western blot as described in Figure 2D.
(B) Mouse xenograft models were established as described in Experimental Procedures. (Top panels) Starting 1 day or at the indicated time after injection of the
human (HeLa) or mouse (LL/2) tumor cells, XMD8-92 was administered twice daily and the tumor growth in these mice was measured every 2 or 3 days. (Lower
panels) Representativemice from each group (control mice on the left) showing the growth of xenograft tumors at the end of an experiment. n = 6mice, ± standard
error of mean (SEM), *p < 0.01.
(C) Fluorescence microscopy images of HeLa or LL/2 tumor sections from XMD8-92 treated or control mice as indicated. The sections were stained with anti-
BrdU antibody or DAPI as noted. n = 6 mice, n = 9 slices. Scale bar represents 10 mm.
(D) Mice were implanted with Matrigel containing 400 ng/mL bFGF. The next day, mice were treated with XMD8-92 or vehicle for 6 days. The Matrigel plugs were
then harvested, sectioned and stained with Masson’s trichrome (n = 6 mice, n = 9 slices.). Hemoglobin content in the Matrigel plugs was assessed as described
(Hayashi et al., 2005). n = 6 mice, ± SEM, *p < 0.01. Scale bar represents 100 mm.
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BMK1 Inhibits PML Activity(5 mg/mL total protein) were incubated in the presence of XMD8-92 at 50 mM,
10 mM, 2 mM, 0.8 mM, and 0 mM for 15 min before addition of the ATP or ADP
acylphosphate probe (5 mM final probe concentration). All reactions were
carried out in duplicate. Probe reactions proceeded for 10min and the reaction
stopped by the addition of urea and processed for MS analysis as described
(Patricelli et al., 2007). Samples were analyzed by LC-MS/MS on a linear ion
trap mass spectrometer using a time segmented ‘‘target list’’ designed to
collect MS/MS spectra from all kinase peptide-probe conjugates that can be
detected in HeLa cell lysates. This target list was generated and validated
by prior exhaustive analysis of HeLa lysates. Up to four characteristic fragment264 Cancer Cell 18, 258–267, September 14, 2010 ª2010 Elsevier Inions for each kinase peptide-probe conjugate were used to extract signals
for each kinase, and a comparison of inhibitor treated to control (untreated)
lysates allowed for precise determination of % inhibition at each point.
A manuscript describing the details of this targeted mass spectrometry
approach is in preparation.
Cell Culture, Stable Isotope Labeling with Amino Acid in Cell Culture
Labeling, and Sample Preparation for MS
GIBCO SILAC DMEM basal cell culture medium (Invitrogen, Carlsbad, CA)
containing 2 mM L-glutamine, 10% dialyzed fetal bovine serum (FBS)c.
Figure 7. Pharmacological Inhibition of BMK1 Suppresses Tumor
Growth through PML
(A) Mouse tumor model with syngeneic LL/2 carcinoma was established as
described in Experimental Procedures. Starting 7 days after injection of LL/2
tumor cells into mice, the mice were treated with intratumoral injection of
recombinant adenovirus encoding BMK1(AEF) [Ad-BMK1(AEF)] or empty
vector control (Ad-EV) as indicated. One day after starting the injection of
recombinant adenoviruses, XMD8-92 was administered to the indicated
mice. n = 6 mice, ± standard error of mean (SEM), *p < 0.01.
(B) Mouse tumor models with PML-knockdown (PML-KD) and control LL/2
carcinoma (Ctrl) were established (middle panel) similar to syngeneic LL/2
tumor model. Starting 7 days after injection of the LL/2 tumor cells, the mice
were treated with XMD8-92 or vehicle for another 9 days as described in (A).
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Can(Invitrogen), and 100 U/ml penicillin and streptomycin was supplemented with
100 mg/l L-lysine and 20 mg/l L-arginine or 100 mg/L [U-13C6]-L-lysine and
20 mg/L [U-13C6,
15N4]-L-arginine (Invitrogen) to make the ‘‘Light’’ SILAC or
‘‘Heavy’’ SILAC culture media, respectively. HeLa cells were obtained from
ATCC and were propagated in SILAC medium for more than nine generations
to ensure nearly 100% incorporation of labeled amino acids before the exper-
iment was performed. After being washed with precooled PBS buffer, HeLa
cells were lysed in E1A (250 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% NP40,
5mMEDTA, protease inhibitor cocktail (Roche, Indianapolis, IN) and phospha-
tase inhibitor cocktail (Roche) or RIPA (13 PBS, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 0.1 mg/ml PMSF, 1 mM sodium orthovanadate,
protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche)
lysis buffer, respectively. Light cell lysate and Heavy lysate were mixed at a 1:1
ratio, and the mixed lysates were incubated with the precipitating antibody for
8 hr, followed by 16 hr incubation with protein G beads (Invitrogen). Immune
complexes were washed three times in lysis buffer (E1A or RIPA, respectively)
and once in sterile water, and then incubated in 8 M urea for 30 min at room
temperature. The supernatant was reduced with DTT, and then alkylated
with iodoacetamide. The resulting samples from E1A or RIPA lysis buffer
were dialyzed against 2 M urea/100 mM NH4HCO3 at 37
C for 5 hr and then
analyzed by multidimensional liquid chromatography coupled with tandem
mass spectrometry (MudPIT) twice. Because the existence of the stable
(heavy) isotope in nature is <1%, any ‘‘light’’ peptide detected by MudPIT
with no similar amount of ‘‘heavy’’ peptide detected was considered as
a contaminant.
In Vivo Tumorigenesis Experiments
The following animal handling and procedures were approved by the Scripps
Institutional Animal Care and Use Committee and followed the National Insti-
tutes of Health guidelines.
HeLa Xenograft Model
HeLa cells (53 105) were resuspended in DMEM and injected subcutaneously
(SC) into the right flank of 6-week-old NOD/SCID mice (day 0). On the second
day (day 1) after tumor cell injection, mice were randomized into two groups
(6 animals [XMD8-92 (1–28 days)] and 18 animals [control]). The XMD8-92
(1–28 days) group was treated with XMD8-92 at the dose of 50 mg/kg twice
a day IP. The control group received daily injections of the carrier solution as
control. On the day 7, the control group was randomized into two groups
(6 animals [XMD8-92 (7–28 days)] and 12 animals [control]). On day 14, the
remaining control group was randomized into two groups (six animals
[XMD8-92 (14–28 days)] and six animals [control]). Treatment with XMD8-92
in XMD8-92 (7–28 days) and XMD8-92 (14–28 days) groups was initiated on
day 7 and day 14, respectively. Tumor size was measured using a caliper,
and tumor volume was determined by using the formula: L3W23 0.52, where
L is the longest diameter and W is the shortest diameter.
LL/2 Xenograft Model
LL/2 cells (13 106) were resuspended in DMEM and injected SC into the right
flank of 6-week-old C57Bl/6 mice (day 0). On the second day (day 1) after
tumor cell injection, mice were randomized into two groups (6 animals
[XMD8-92 (1–17 days)] and 18 animals [control]). The XMD8-92 (1–17 days)
group was treated with XMD8-92 at the dose of 50 mg/kg twice a day intraper-
itoneally. The control group received daily injections of the carrier solution as
control. On the day 7, the control group was randomized into two groups
(6 animals [XMD8-92 (7–17 days)] and 12 animals [control]). And on the
day 14, the remaining control group was randomized into two groups (six
animals [XMD8-92 (10–17 days)] and six animals [control]). Treatment with
XMD8-92 in XMD8-92 (7–17 days) and XMD8-92 (10–17 days) groups was initi-
ated on day 7 and day 10, respectively.
Recombinant Adenovirus Treatment
LL/2 cells (1 3 106) were injected SC into C57Bl/6 mice (day 0). Recombinant
adenoviral particles were generated as described in our previous study(Bottom panel) Mice bearing PML-KD LL/2 tumors for 7 days were injected
with recombinant adenovirus encoding wild-type PML [Ad-PML], mutant
PML [Ad-PML2D], or empty vector control [Ad-EV] intratumorally. One day
after starting the injection of recombinant adenoviruses, XMD8-92 or vehicle
was administered to the indicated mice. n = 6 mice, ± SEM, *p < 0.01.
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BMK1 Inhibits PML Activity(Hayashi et al., 2001). On the day 7, mice were randomized into four groups
[Ad-EV, Ad-BMK1(AEF), Ad-EV+XMD8-92, and Ad-BMK1(AEF)+XMD8-92]
(six animals per group). Mice were injected intratumorally (IT) with either
empty adenovirus (Ad-EV) or recombinant adenovirus encoding BMK1(AEF)
[Ad-BMK1(AEF)] on day 7, day 11, day 15, day 19, using the procedure
previously described (Kim et al., 2004). Ad-EV+XMD8-92 and Ad-BMK1
(AEF)+XMD8-92 groups were treatedwith XMD8-92 fromday 8 to day 20 using
the procedure described in the LL/2 xenograft model. The other two groups
[Ad-EV and Ad-BMK1(AEF)] received injections of the carrier solution instead
as control.
PML Reconstitution
PML shRNAi knockdown and control cell lines were built using pGIPZ-shRNA-
mir-PML (Lentiviral) and pGIPZ (Lentiviral) plasmids from Openbiosystems
(Huntsville, AL). Knockdown (1 3 106) (48 animals) or control (12 animals)
LL/2 cells were injected SC into C57Bl/6 mice (day 0). On the second
day (day 1) after tumor cell injection, mice were randomized into 10 groups
(six animals per group) [KD, Ctrl, KD+XMD8-92 and Ctrl+XMD8-92; KD+
Ad-EV, KD+Ad-PML, KD+Ad-PML2D(S403D/T409D), KD+Ad-EV+XMD8-92,
KD+Ad-PML+XMD8-92, and KD+Ad-PML2D(S403D/T409D)+XMD8-92]. The
KD+XMD8-92 and Ctrl+XMD8-92 groups were treated with XMD8-92 at the
dose of 50 mg/kg twice a day IP for 16 days. The KD and Ctrl groups received
daily injections of the carrier solution as control for 16 days. The KD+Ad-EV,
KD+Ad-PML, KD+Ad-PML2D, KD+Ad-EV+XMD8-92, KD+Ad-PML+XMD8-
92, and KD+Ad-PML2D+XMD8-92 groups were injected IT with either empty
adenovirus (Ad-EV), Ad-PML, or Ad-PML2D recombinant adenovirus encod-
ing PML or PML2D on day 7, day 11, day 15, day 19, using the procedure
previously described (Kim et al., 2004). KD+Ad-EV+XMD8-92, KD+Ad-PML+
XMD8-92, and KD+Ad-PML2D+XMD8-92 groups were treated with XMD8-92
from day 8 to day 20 using the procedure described in the LL/2 xenograft
model. The KD+Ad-EV and KD+Ad-PML and KD+Ad-PML2D groups received
injections of the carrier solution instead as control.
A549 Xenograft Model
To ascertain that XMD8-92 can block BMK1 in vivo, 13 106 A549 cells, whose
endogenous BMK1 autophosphorylation was detectable by western blotting,
were resuspended in DMEM and injected SC into the right flank of 6-week-old
NOD/SCID mice. On the 21st day after the injection, mice were randomized
into two groups (two animals per group). One group was treated with
XMD8-92 at the dose of 50 mg/kg twice a day. The other group was treated
with the carrier solution as control. After 2 days, the A549 tumor was homog-
enized in E1A buffer followed by western blot analysis.
The effectiveness of BMK1 inhibition in xenograft tumors was shown in the
Supplemental Information (Figure S5).Statistical Analysis
p values were calculated with the Student’s t test.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and six tables and can be found
with this article online at doi:10.1016/j.ccr.2010.08.008.ACKNOWLEDGMENTS
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